Nomura keeps JPY 3,800.00 target for Daiichi Sankyo stock

Published on 10/15/2026 at 22:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Daiichi Sankyo reports on October 30, 2026. Daiichi Sankyo stock costs EUR 14.98 on October 15, 2026 at 10:45 p.m. CEST.

Key numbers for Daiichi Sankyo

Nomura maintained its Buy rating and JPY 3,800.00 target on October 13, 2026.
Daiichi Sankyo's next financial results briefing is scheduled for October 30, 2026.
Daiichi Sankyo stock costs EUR 14.98 at Lang & Schwarz on October 15, 2026 at 10:45 p.m. CEST.
The company had a market capitalization of JPY 4.8 trillion and a P/E ratio of 20.08 on October 15, 2026.

Daiichi Sankyo, JP3475350009, Illustration mit AI erstellt.

Nomura maintained its Buy rating on Daiichi Sankyo and set a JPY 3,800.00 price target in a report dated October 13, 2026, according to Markets Insider. The target was 43.34 percent above the Tokyo price of JPY 2,651.00 used for the comparison. Daiichi Sankyo stock costs EUR 14.98 at Lang & Schwarz on October 15, 2026 at 10:45 p.m. CEST.

Results date is October 30

Daiichi Sankyo has scheduled its fiscal 2026 second-quarter financial results briefing for October 30, 2026, according to the company's investor-relations calendar at Daiichi Sankyo. The date gives investors the next fixed point for testing whether oncology growth is translating into earnings momentum.

The yearly range leaves room

On the TSE, Daiichi Sankyo last traded at JPY 2,651.00 on October 15, 2026 at 3:30 p.m. JST, with a 1.92 percent daily gain. The German euro quotation stood inside a 52-week range of EUR 13.20 to EUR 23.75 on October 15, 2026. At EUR 14.98, the Lang & Schwarz price was 13.48 percent above the range low and 36.93 percent below the high.

The TSE session also registered 8,041,900 shares of volume against an average of 6,372,974 shares. That is 26.19 percent above the average, making the Tokyo move more substantial than a thin-market print.

Valuation and peer levels

Daiichi Sankyo's market capitalization was JPY 4.8 trillion, its trailing P/E ratio was 20.08 and its dividend yield was 0.03 percent on October 15, 2026. The next results date matters because the June-quarter figures cited in recent coverage are already reflected in the current valuation picture.

Comparison with peers

DAIICHI SANKYO: P/E 20.08, market capitalization JPY 4.8 trillion.

Takeda Pharmaceutical (TSE, JPY): plus 4.99 percent, P/E 55.12, market capitalization JPY 9.8 trillion.

Chugai Pharmaceutical (TSE, JPY): plus 3.76 percent, P/E 21.88, market capitalization JPY 10.3 trillion.

Price stays near the lower range

The comparison places Daiichi Sankyo below the middle of its 52-week euro range, while its Tokyo valuation remains close to Chugai's P/E and well below Takeda's multiple. The October 30 results briefing is the next dated event for investors tracking whether the company's oncology portfolio can support the premium attached to its pipeline.

The further course of trading is shown by the continuously updated real-time quote of Daiichi Sankyo stock.